<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1919-1257'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/profile/">Profile</a>
<span>Myeloma Panel 4</span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">Myeloma Panel 4 </h1>
<div class="post-text">
<p>Myeloma Panel 4 is an integrated diagnostic approach that combines Flow Cytometry (FCM) Multiple Myeloma (MM) Panel, Karyotyping, and Fluorescence In Situ Hybridization (FISH) for specific markers (17p, del13q, IgH, t(4;14), and t(14;16)). This comprehensive approach helps in the diagnosis, risk stratification, and management of multiple myeloma. </p>
<p>Multiple myeloma is a malignancy of plasma cells characterized by the production of abnormal monoclonal immunoglobulins. These malignant plasma cells accumulate in the bone marrow, suppressing the formation of normal blood cells. Myeloma Panel 4 combines the FCM MM Panel, Karyotyping, and FISH for several chromosomal markers. This comprehensive approach not only helps in diagnosing multiple myeloma but also in understanding the genetic complexity of the disease, which is vital for risk stratification and management. <br><br>
Flow cytometry is a technique used to analyze the physical and chemical characteristics of particles in a fluid as it passes through at least one laser. Cell components are fluorescently labeled and then excited by the laser to emit light at varying wavelengths.<br><br>
In the context of multiple myeloma, flow cytometry helps to identify abnormal plasma cells by analyzing the expression of specific cell surface markers. This technique can be used to differentiate between normal and malignant plasma cells, estimate the tumor burden, and assess the response to therapy.
Karyotyping is a laboratory procedure that allows the visualization of an individual's chromosomes. In multiple myeloma, karyotyping is used to detect chromosomal abnormalities that could not be identified using standard microscopy. While karyotyping provides an overview of chromosomal abnormalities, it is less sensitive compared to FISH for detecting specific genetic changes.<br><br>
Fluorescence In Situ Hybridization (FISH) is a molecular cytogenetic technique that uses fluorescent probes that bind to only those parts of the chromosome with which they show a high degree of sequence complementarity. FISH is used for detecting and locating specific DNA sequences on chromosomes. </p>
<p>The FISH analysis in Myeloma Panel 4 is targeted at specific markers:</p>
<ol>
	<li style="font-size: 15px";><b>17p Deletion:</b>Deletion of the short arm of chromosome 17 is associated with a high-risk disease and poor prognosis.</li>
	<li style="font-size: 15px";><b>del13q (Deletion 13q): </b>Deletion of the long arm of chromosome 13. This is common in multiple myeloma and is associated with disease progression.</li>
	<li style="font-size: 15px";><b>IgH (Immunoglobulin Heavy Chain) Breakapart:</b>Assesses rearrangements of the immunoglobulin heavy chain locus, which is a common event in multiple myeloma.</li>
	<li style="font-size: 15px";><b>t(4;14) (Translocation between chromosomes 4 and 14): </b>This translocation is associated with poor prognosis.</li>
	<li style="font-size: 15px";><b>t(14;16) (Translocation between chromosomes 14 and 16):</b>This is less common but is associated with aggressive disease and a poor prognosis.</li>
</ol>
<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Profile Name</th>
			<td scope="col">Myeloma Panel 4</td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Bone Marrow </td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>No special preparation is needed for this test. </td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>refer individual test </td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>â‚¹ 21000 </td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
	<h2 class="test-h2 mt-3"> Why is Myeloma Panel 4 considered comprehensive? </h2>
	<p>Myeloma Panel 4 is comprehensive because it combines multiple diagnostic modalities, including flow cytometry, karyotyping, and FISH for specific genetic markers. This allows for a more detailed assessment of the disease. </p>
	<h2 class="test-h2 mt-3">How is the sample collected for Myeloma Panel 4? </h2>
	<p>A bone marrow aspiration procedure is performed to collect the sample needed for Myeloma Panel 4. </p>
	<!--section achieved-->
	<?php include "../../include/iconsbox.php" ?>
	<!--//section achieved-->
	<h2 class="test-h2 mt-3">Can this panel detect minimal residual disease (MRD)? </h2>
	<p>Flow cytometry in this panel can be used as part of an assessment for minimal residual disease, helping to determine how deep the response to therapy is. </p>
	<h2 class="test-h2 mt-3">How does the panel affect treatment decisions? </h2>
	<p>The results from Myeloma Panel 4 can inform treatment decisions by identifying high-risk features that might warrant more aggressive therapy. </p>
	<h2 class="test-h2 mt-3">Can the test be done with peripheral blood? </h2>
	<p>Bone marrow is the preferred sample type because the malignant plasma cells primarily reside in the bone marrow. </p>
	<h2 class="test-h2 mt-3"> How long will it take to get the results? </h2>
	<p>The turnaround time for Myeloma Panel 4 is usually 12-18 days. </p>
	<h2 class="test-h2 mt-3">Is the test covered by insurance? </h2>
	<p>Coverage for this test varies by insurance providers. It is recommended to consult your insurance company to determine if this test is covered under your policy. </p>
	<h2 class="test-h2 mt-3">How should the results be interpreted? </h2>
	<p>The interpretation of Myeloma Panel 4 should be carried out by a hematologist or oncologist who specializes in multiple myeloma. <br><br>
Multiple myeloma is a genetically complex disease, and understanding its molecular and cytogenetic characteristics is crucial for effective management. Myeloma Panel 4, with its integrated approach, offers valuable insights into the genetic abnormalities associated with multiple myeloma, helping clinicians in diagnosis, risk stratification, and devising personalized treatment plans. Patients should work closely with their healthcare provider to understand the results of this panel and the implications for their treatment and prognosis. </p>
	
</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>